Michael Brian Bell Sells 2,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $128.62, for a total transaction of $257,240.00. Following the sale, the chief financial officer directly owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Brian Bell also recently made the following trade(s):

• On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The shares were sold at an average price of $87.04, for a total transaction of $261,120.00.

Guardant Health Stock Performance

Shares of NASDAQ GH traded down $0.72 during midday trading on Monday, reaching $124.89. The stock had a trading volume of 2,213,881 shares, compared to its average volume of 2,140,162. The stock has a 50-day moving average of $99.39 and a 200-day moving average of $101.12. The company has a market capitalization of $16.56 billion, a price-to-earnings ratio of -36.84 and a beta of 1.61. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $134.28.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GH. AQR Capital Management LLC boosted its holdings in shares of Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after purchasing an additional 25,831 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Guardant Health during the 1st quarter valued at about $274,000. Sei Investments Co. boosted its holdings in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after purchasing an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after purchasing an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after purchasing an additional 40,209 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the subject of several recent analyst reports. Barclays upped their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Canaccord Genuity Group upped their target price on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Stifel Nicolaus upped their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Wells Fargo & Company upped their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $139.80.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.